By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Life Care NewsLife Care NewsLife Care News
  • Home
  • Business
    • Business
  • News
  • Tech
  • Entertainment
  • Health
  • Education
  • Automobile
  • Sports
Search
Technology
  • Advertise
  • Advertise
Health
Entertainment
  • Home
  • Business
    • Business
  • News
  • Tech
  • Entertainment
  • Health
  • Education
  • Automobile
  • Sports
  • Advertise
  • Advertise
Copyright © 2015 - 2024 LifeCareNews Network. All Rights Reserved.
LIFE CARE IS REGISTERED MAGAZINE IN RNI, NO.GUJGUJ/2015/71283
Reading: IAS INVESTOR ALERT: Kirby McInerney LLP Notifies Integral Ad Science Holding Corp. Investors of Upcoming Lead Plaintiff Deadline in Class Action Lawsuit
Share
Notification Show More
Font ResizerAa
Life Care NewsLife Care News
Font ResizerAa
  • Education
  • Automobile
  • Entertainment
  • News
  • Tech
  • Sports
Search
  • Home
  • Home
    • Home 1
    • Default Home 5
  • Categories
  • Categories
    • Tech
    • Entertainment
    • Automobile
    • Sports
    • Education
    • News
    • Health
  • Bookmarks
  • Bookmarks
  • More Foxiz
    • Sitemap
  • More Foxiz
    • Sitemap
Follow US
  • Advertise
  • Advertise
Copyright © 2015 - 2024 LifeCareNews Network. All Rights Reserved. LIFE CARE IS REGISTERED MAGAZINE IN RNI, NO.GUJGUJ/2015/71283
Business

IAS INVESTOR ALERT: Kirby McInerney LLP Notifies Integral Ad Science Holding Corp. Investors of Upcoming Lead Plaintiff Deadline in Class Action Lawsuit

Business Wire
Last updated: 22/02/2025 10:53 AM
Business Wire
Share
5 Min Read
IAS INVESTOR ALERT: Kirby McInerney LLP Notifies Integral Ad Science Holding Corp. Investors of Upcoming Lead Plaintiff Deadline in Class Action Lawsuit
SHARE
IAS INVESTOR ALERT: Kirby McInerney LLP Notifies Integral Ad Science Holding Corp. Investors of Upcoming Lead Plaintiff Deadline in Class Action Lawsuit

NEW YORK–(BUSINESS WIRE)–$IAS #CLASSACTIONLAWSUIT–The law firm of Kirby McInerney LLP reminds investors of the March 31, 2025, deadline to seek the role of lead plaintiff in a federal securities class action filed on behalf of investors who acquired Integral Ad Science Holding Corp. (“IAS” or the “Company”) (NASDAQ:IAS) securities during the period from March 2, 2023, through February 27, 2024 (“the Class Period”).


[LEARN MORE ABOUT THE CLASS ACTION]

IAS is a global software company specializing in digital advertising and offers a suite of digital ad verification and optimization solutions. The ad verification industry is dominated by IAS and its main competitor DoubleVerify, Inc. (“DoubleVerify”), constituting a “virtual duopoly”. As such, concerns over a potential pricing war with DoubleVerify have led the Company to reassure investors about its ability to defend pricing.

- Advertisement -

Unbeknownst to investors, by February 23, 2023, senior management at IAS was aware that demand had started to slow. In a non-public presentation, senior management told the Board of Directors (“Board”) of the Company was experiencing “pricing pressure” in its ad verification and optimization businesses, and that the Company had resorted to cutting rates when renewing and securing new contracting, leading to fee compression.

On August 3, 2023, after the market closed, IAS reported its second quarter financial results revealing that the growth of its optimization revenue had meaningfully slowed. On this news, the price of IAS shares declined by $3.66 per share, or approximately 19.4%, from $18.83 per share on August 3, 2023, to close at $15.17 on August 4, 2023.

However, the Company continued to conceal that pricing pressure was a key factor underlying the Company’s slowing revenue growth. During an August 3, 2023, earnings call to discuss second quarter results, analysts asked about the Company’s pricing. CFO Tania Secor pivoted, instead blaming “maturing Context Control growth” and “slower demand from tech/telco clients.”

On February 27, 2024, after the market closed, IAS reported fourth quarter financial results for 2023 and announced lackluster revenue guidance below analysts’ estimates. On an earnings call that same day, the Company admitted that these disappointing revenue numbers resulted from pricing cuts issued to customers across the Company’s measurement and optimization businesses. CEO Lisa Utzchneider stated, “we are seeing more competitive pricing in measurement on a select group of large contract renewals in exchange for increased volume commitments and multi-year exclusive agreements.” On this news, the price of IAS shares declined by $7.09 per share, or approximately 41%, from $17.10 per share on February 27, 2024, to close at $10.01 per share on February 28, 2024.

The complaint alleges that defendants, throughout the Class Period, misrepresented and/or failed to disclose that: (1) that IAS was experiencing a new material trend of increased competitive pricing pressures and that, as a result, IAS had been forced to cut prices to compensate for weakening demand and slowing revenue growth; (2) that IAS’s pricing function was no longer ‘favorable’ and IAS could not sustain its pricing and drive price increases; (3) that pricing had become a key differentiator between IAS and its competitor necessary to close major renewals and new deals; and (4) that the risk that competition “could result in increased pricing pressure” or “could put pressure on us to change our prices” had in fact transpired.

- Advertisement -

If you purchased or otherwise acquired IAS securities, have information, or would like to learn more about this investigation, please contact Thomas W. Elrod of Kirby McInerney LLP by email at investigations@kmllp.com, or fill out the form below, to discuss your rights or interests with respect to these matters without any cost to you.

[CONTACT FORM]

Kirby McInerney LLP is a New York-based plaintiffs’ law firm concentrating in securities, antitrust, whistleblower, and consumer litigation. The firm’s efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars. Additional information about the firm can be found at Kirby McInerney LLP’s website.

- Advertisement -

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts

Kirby McInerney LLP

Thomas W. Elrod, Esq.

212-699-1180

https://www.kmllp.com
investigations@kmllp.com

You Might Also Like

CGTN: From Chancay to Shanghai: Transforming Latin America’s trade future

iHit Redefines Industry Standards: 2025 North American Vape Hybrid RevolutionHybrid-Coil Heating Technology 1+1>2, Unlocking Next-Gen Vaping Experience

Timbertales, A Luxurious New Escape, Opens in Coorg

Spineway provides an update on its activities during a webinar – Arrival of a new CFO

Swift Navigation and KDDI LaunchSkylark Precise Positioning Service Across Japan

TAGGED:acquiredactionbehalfclassclassactionlawsuitthecompanydeadlinedigitaldoubleverifyfederalfiledfirmholdingiasintegralinvestorinvestorskirbylawlawsuitleadllpmarchmcinerneynotifiesperiodplaintiffpricingremindsroleSciencesecuritiesseekuncategorizedupcomingverificationwire$iasyorkbusiness

Sign Up For Daily Newsletter

Be keep up! Get the latest breaking news delivered straight to your inbox.

By signing up, you agree to our Terms of Use and acknowledge the data practices in our Privacy Policy. You may unsubscribe at any time.
Share This Article
Facebook Twitter Copy Link Print
Share
Previous Article Oldcastle APG Showcases Complete Product Portfolio at International Builders Show Oldcastle APG Showcases Complete Product Portfolio at International Builders Show
Next Article Certain BlackRock Funds Announce Expiration and Preliminary Results of Tender Offers Certain BlackRock Funds Announce Expiration and Preliminary Results of Tender Offers

Stay Connected

FacebookLike
TwitterFollow
PinterestPin
InstagramFollow
YoutubeSubscribe
Google NewsFollow
LinkedInFollow
MediumFollow
- Advertisement -

Latest News

AVEROA receives European marketing authorization for XOANACYL, an Oral Therapy for Chronic Kidney Disease (CKD)
AVEROA receives European marketing authorization for XOANACYL, an Oral Therapy for Chronic Kidney Disease (CKD)
Health 16/06/2025
ITM and ILL Extend Collaboration on the Manufacturing and Supply of Medical Lutetium-177 Radioisotope
ITM and ILL Extend Collaboration on the Manufacturing and Supply of Medical Lutetium-177 Radioisotope
Health 16/06/2025
Roche to advance prasinezumab into Phase III development for early-stage Parkinson’s disease
Roche to advance prasinezumab into Phase III development for early-stage Parkinson’s disease
Health 16/06/2025
EHA 2025 | Multiple Studies Report Encouraging Data of Olverembatinib in Ph+ ALL
EHA 2025 | Multiple Studies Report Encouraging Data of Olverembatinib in Ph+ ALL
Health 16/06/2025
//

We increase the awareness of millions of users through our news networks. We are one of the most trusted news networks in the world.

Quick Link

  • About Us
  • Contact Us
  • Editorial Guidelines
  • Privacy Policy
  • Terms and Conditions

Top Categories

  • Automobile
  • Education
  • Entertainment
  • Health
  • News
  • Sports
  • Tech

Sign Up for Our Newsletter

Subscribe to our newsletter to get our newest articles instantly!

Life Care NewsLife Care News
Follow US
Copyright © 2015 - 2024 LifeCareNews Network. All Rights Reserved. LIFE CARE IS REGISTERED MAGAZINE IN RNI, NO.GUJGUJ/2015/71283
Join Us!
Subscribe to our newsletter and never miss our latest news, podcasts etc..

Zero spam, Unsubscribe at any time.
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?